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An assay device for the rapid detection of Leptospira-specific immunoglobulin M (IgM) antibodies in human
sera is presented. The sensitivity (85.8%) and specificity (93.6%) of the assay compared well (91.9% agreement)
with those of an IgM enzyme-linked immunosorbent assay routinely used in the serodiagnosis of leptospirosis.
The sensitivity of the assay varied with the stage of the disease. The assay uses stabilized components and is
simply performed by the addition of serum and sample fluid to the sample well of the assay device. The assay
is read after 10 min, and a positive result is obtained when staining of the test line is observed.
As the clinical symptoms and signs of leptospirosis often are
nonspecific, the disease is easily mistaken for other major in-
fectious diseases. Manifestations of leptospirosis may vary, and
different types of disease may be observed, from relatively mild
influenza-like symptoms to severe disease with renal failure,
liver impairment, and haemorrhage (Weil’s syndrome). Men-
ingismus and (aseptic) meningitis can be observed as well.
Because of the wide variety of symptoms, leptospirosis is easily
confused with many other fibril illnesses including haemor-
rhagic fevers, e.g., dengue fever (7). Laboratory testing to
confirm the clinical diagnosis thus is essential for optimal treat-
ment and patient management. The laboratory diagnosis of
leptospirosis mainly depends on serology (8). The microscopic
agglutination test (MAT) (5, 31) is considered the reference
test for leptospirosis, but the enzyme-linked immunosorbent
assay (ELISA) (2, 15–17, 19, 32, 34, 36) and a number of other
tests including the immunofluorescent-antibody test (IFAT)
(3), the slide agglutination test (9), the macrocapsule aggluti-
nation test (4), and the hemagglutination test (13, 28, 29) can
be used as well. Drawbacks of the standard diagnostic assays
like MAT, ELISA, and IFAT are that they are not very easy to
perform, require special and expensive equipment, depend on
the availability of electricity and refrigeration, or can be ap-
plied only by trained personnel. Hence, these assays are avail-
able only in a few specialized laboratories. MAT, which is
considered the reference test for leptospirosis, is rarely per-
formed by routine diagnostic laboratories.
Leptospirosis has been reported from countries all over the
world (1). Sporadic cases of leptospirosis may occur in coun-
tries with moderate climates. The disease, however, can be
endemic in countries with wet and warm climates. People living
under poor socioeconomical and hygienic conditions are at
particular risk of getting the disease. Outbreaks have been
reported (6, 11, 12, 14, 20–23, 27, 30, 33). Most people at risk
cannot depend on health care facilities supported by laborato-
ries capable of performing the more complicated standard
laboratory assays. We previously developed a dipstick assay for
the detection of Leptospira-specific immunoglobulin M (IgM)
antibodies in human sera (10, 20, 24–26, 35). This assay can be
used outside the specialized laboratory and may even be used
in the field. As the assay takes 3 h to develop, we have aimed
at developing an assay which gives a quicker result. Here we
describe a lateral-flow assay for the detection of Leptospira-
specific IgM antibodies in human sera. The assay uses a broad-
ly reactive leptospiral antigen to bind to Leptospira-specific
antibodies present in the serum and a colloidal gold-labeled
anti-human IgM antibody as the detection reagent. The assay
is performed by the addition of serum and sample fluid and can
be read after 10 min. An immunoblot assay for the detection of
Leptospira-specific IgM antibodies with a gold-labeled conju-
gate has been reported (18).
MATERIALS AND METHODS
Lateral-flow assay. The lateral-flow assay consists of a detection strip made of
nitrocellulose that is flanked at one end by a reagent pad that contains the dried
colloidal gold-labeled anti-human IgM antibody and at the other end by an
absorption pad. A sample application pad in turn flanks the reagent pad. Heat-
resistant antigen was prepared from a nonpathogenic leptospiral strain (strain
Patoc I) by boiling of a washed and concentrated bacterial culture. The boiled
suspension was centrifuged to remove cell debris, and the supernatant containing
the antigen was filtered. The antigen was deposited as a 1-mm narrow line onto
the nitrocellulose strip. Human IgM was deposited in a second line parallel to the
antigen line to function as a reagent control. The composite was backed by a
support and was cut into 5-mm-wide test strips to fit a plastic housing with a
round sample application well positioned above the sample pad and a square
detection window positioned above the detection strip. The amounts of antigen
and detection reagent were optimized in a step-by-step procedure with a panel of
positive and negative control sera. The assay is performed by the addition of 5 ml
of undiluted serum followed by the addition of 130 ml of sample fluid. The
sample fluid consists of phosphate-buffered saline containing 0.66 mg of bovine
serum albumin per ml and 3% Tween 20. The assay is scored positive when a
distinct staining of the antigen line is observed. When no staining is observed the
test is negative. To increase stability, the devices are individually packed in a
moisture-resistant sachet made from plastic-coated aluminum foil. Sealed assay
devices can be stored for at least 1 year between 4 and 28°C and for 6 months at
45°C without showing a loss of activity.
* Corresponding author. Mailing address: Department of Biomedi-
cal Research, Royal Tropical Institute, Meibergdreef 39, 1105 AZ
Amsterdam, The Netherlands. Phone: 31 20 5665470. Fax: 31 20
6971841. E-mail: H.Smits@kit.nl.
166
 by on S
eptem







Evaluation studies. The sensitivity and specificity of the lateral flow assay were
determined by testing single and paired samples from(i) 135 patients with lab-
oratory-confirmed cases of leptospirosis (case patients; 268 samples), (ii) 138
controls (212 samples), and (iii) 147 patients with various diseases other than
leptospirosis (167 samples), including patients with human immunodeficiency
virus infection, hepatitis A, hepatitis B, syphilis, malaria, toxoplasmosis, menin-
gitis, meningococcal meningitis, Lyme borreliosis, hantavirus infection, and au-
toimmune disease and rheumatoid factor-positive patients. The samples from
the case patients and controls had been referred for confirmation because of
suspicion of leptospirosis to laboratories in hospitals in Hawaii (15 case patients
and 36 controls), Indonesia (41 case patients and 15 controls), The Netherlands
(37 case patients and 62 controls), and the Seychelles (42 case patients and 25
controls). The suspected patients had been stratified as case patients and controls
on the basis of the results of the MAT, which was performed and whose results
were interpreted by routine diagnostic procedures. Paired samples from some
(57.0%) of the case patients showed seroconversion or a fourfold or greater rise
in MAT titer, and paired samples from some (41.4%) of the case patients showed
MAT titers of $1:160 without showing a fourfold or greater rise. Two (1.6%)
case patients for which single samples were available had MAT titers of $1:160.
MATs for the samples from Indonesia and The Netherlands were performed at
the laboratory of the Royal Tropical Institute in Amsterdam. All samples were
also tested by the IgM ELISA performed with antigen prepared from strain
Wijnberg (serovar copenhageni). The IgM ELISA and lateral-flow test were
performed at the laboratory of the Royal Tropical Institute. Culture was per-
formed for the samples from The Netherlands only and confirmed the results of
the MAT for five patients.
To study the clinical utility of the lateral-flow assay, the assay was applied in a
district hospital in India to 101 samples collected during the first week of hos-
pitalization from 90 consecutive patients admitted with clinical suspicion of
leptospirosis in November and December 1999. As a confirmatory test the IgM
ELISA with antigen prepared from strain Patoc I was applied.
RESULTS AND DISCUSSION
A positive result in the lateral-flow assay for one or both
samples was obtained for 116 of the 135 case patients, for 9 of
the 138 controls, and for 19 of the 145 patients with a disease
other than leptospirosis. The overall sensitivity of the lateral-
flow assay thus was calculated to be 85.8% (95% confidence
interval [CI], 79 to 91%), and the overall specificity was 93.6%
(95% CI, 88 to 97%). The selectivity of the assay as calculated
for the group of patients with a disease other than leptospirosis
was 88.4% (95% CI, 82 to 93%). Cross-reactivity at a weak
staining intensity in particular was observed for samples from
patients with meningitis and for rheumatoid factor-positive
samples. For comparison, the overall sensitivity of the IgM
ELISA was 89.3% (95% CI, 82 to 94%), and the overall spec-
ificity of this assay was 94.2% (95% CI, 89 to 97%). The
sensitivity of the lateral-flow assay for patients showing sero-
conversion or a fourfold or greater rise in MAT titer was
higher than the sensitivity for the group of case patients not
meeting these criteria. The sensitivities for the two groups were
90.9 and 79.3%, respectively. Similar differences in sensitivity
of 92.2 and 82.7%, respectively, for the two groups of patients
were noted for the IgM ELISA. Demonstration of seroconver-
sion or a fourfold or greater rise in titer by MAT is consistent
with acute disease. Agglutination in the MAT at an elevated
level for paired sera without a fourfold or greater rise in titer
is consistent with leptospirosis but does not provide evidence
of acute disease. Specific IgM antibodies usually appear 5 to 6
days after the onset of the disease and remain present at ele-
vated levels for a few months. Agglutinating antibodies react-
ing in the MAT may remain present for a much longer period.
The lateral-flow assay like the IgM ELISA demonstrates the
presence of specific IgM antibodies and aims at the identifica-
tion of patients with acute or recent leptospirosis. The absence
of specific IgM antibodies as demonstrated by the IgM ELISA
in some of the patients who did not show seroconversion in the
MAT or a fourfold or greater rise in MAT titer may indicate
that the samples had been collected relatively late in the dis-
ease or that these patients suffered from a disease other than
leptospirosis but still had specific agglutinating antibodies from
a previous infection.
The sensitivity of the lateral-flow assay was 65.9% for sam-
ples collected during the first 10 days of the disease and 80.9%
for samples collected 10 to 30 days after the onset of the
disease (Table 1). The specificities for these two groups were
93.3 and 96.2%, respectively. This result shows that the lateral-
flow assay has a relatively high sensitivity for samples collected
early in the course of disease. The sensitivity of the lateral-flow
device was higher than that of the IgM ELISA and was only
slightly lower than that of MAT for samples collected early in
the course of disease (Table 1). The detection rate of the
lateral-flow assay for samples collected more than 10 days after
the onset of the disease, however, was lower than those of the
IgM ELISA and MAT. Compared with MAT and the IgM
ELISA, the lateral-flow assay had a somewhat larger number
of false-positive results. The results of the lateral-flow assay
and the IgM ELISA showed 91.9% agreement (for agreement
beyond chance, kappa 5 0.83 and 95% CI 5 0.74 to 0.92%).
The maximum value of kappa is 1.0. A kappa value of .0.8
demonstrates almost perfect agreement.
Application of the lateral-flow assay in a district hospital in
India to a group of consecutively admitted patients with clin-
ical suspicion of leptospirosis again revealed a high rate of
concordance with the results of the IgM ELISA (90.1% agree-
ment; kappa, 0.80 [95% CI, 0.62 to 0.98%]). In this study the
lateral-flow assay gave a correct positive result for the samples
collected from 90.7% (39 of 43) of the patients with a positive
result (titer, $1:80) by the IgM ELISA. A correct negative
result was obtained for 87.2% (41 of 47) of the patients with a
negative result (titer, ,1:80) by the IgM ELISA. A positive
result by the lateral-flow test was obtained for a total of 50
samples, of which 35 gave strong staining and 15 gave weak
staining. For comparison, by the IgM ELISA moderate to high
titers (.1:80) were obtained for 32 samples, a borderline titer
(1:80) was obtained for 17 samples, and a titer just below the
cutoff value was obtained for 4 samples. Of the 15 samples that
gave weak staining by the lateral-flow assay, 2 tested negative
by the IgM ELISA, 2 had titers below the cutoff value, 6 had
borderline titers, and 3 had titers above the cutoff value. These
TABLE 1. Test results of the LEPTO lateral-flow device according
to duration of disease and comparison with results
of MAT and IgM ELISA
Time (days) after onset
of disease and test
% Samples (95% CI):
Positive Negative
#10
Lateral-flow assay 65.4 (57–74) 93.3 (88–98)
MAT 69.5 (61–77) 98.6 (94–100)
ELISA 56.7 (48–56) 95.9 (90–99)
.10
Lateral-flow assay 80.9 (72–87) 96.2 (90–99)
MAT 93.6 (88–97) 98.8 (92–100)
ELISA 84.3 (77–90) 98.8 (92–100)
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results demonstrate that the lateral-flow assay allows rapid
confirmation of results for patients with symptoms suspicious
for leptospirosis even when samples from a collection of sam-
ples with a high proportion with borderline or low titers are
tested. As the result of the lateral-flow assay can be obtained
shortly after drawing of the blood sample, application of the
assay will likely improve the treatment of the patients by al-
lowing a better diagnosis to be made and treatment to be
started promptly.
Many different serovars of Leptospira exist, and serovar-
specific antibodies can be detected in agglutinating antibody
assays such as MAT that use live leptospiras as antigen. The
so-called genus-specific antibody assays such as ELISA that are
based on denatured antigens and that are aimed at the detec-
tion of IgM antibodies react with antibodies to many serovars.
The results of this study show that the lateral-flow test reacts
with antibodies to at least serovars australis, autumnalis, bata-
viae, canicola, celledoni, cynopteri, grippotyphosa, icterohae-
morrhagiae, javanica, pomona, sejroe, shermani, and tarassovi.
As the lateral-flow test is read by visual inspection for stain-
ing of the antigen line, reading of the test is subjective for
samples giving a weak staining. A weak positive result may be
due to cross-reactivity or may correlate with low or borderline
titers in the IgM ELISA. Weak positive results by the lateral-
flow assay, like low or borderline in an ELISA, should be
confirmed by testing of a second sample collected at a later
stage to look for an increase in antibody level. The lateral-flow
assay has some major advantages compared with the standard
reference tests. The lateral-flow assay is quick and can be
performed by modestly trained personnel simply by following
the instructions provided in a short instruction leaflet. The
assay does not require expensive equipment, and as the com-
ponents are stabilized, they do not depend on refrigeration for
storage. No electricity is required to perform the assay. Taken
together, these characteristics make the assay ideal for use in
situations in which adequate laboratory facilities for perfor-
mance of the more complicated standard confirmatory assays
are lacking. The lateral-flow assay potentially can be used
outside the laboratory and can be used in district hospitals and
primary health posts or even in the field.
The result of the lateral-flow assay should be interpreted
with respect to the clinical findings. As seroconversion usually
takes place 5 to 7 days after the onset of the disease, the
sensitivity and negative predictive value are relatively low for
samples collected early in the course of the disease. From the
results of this study a sensitivity of 65.9% was calculated for
samples collected during the first 10 days after the onset of
illness. The negative predictive value at this stage of the disease
was calculated to be 68.3%. The sensitivity (80.9%) and neg-
ative predictive value (73.5%) increase for samples collected at
a later stage. Therefore, it is advisable that a second serum
sample drawn one or a few days after collection of the first
sample be tested when a negative result is obtained with the
first sample but when clinical suspicion of leptospirosis re-
mains. The epidemiological situation should also be consid-
ered when interpreting the assay result. As the specificity of the
assay was calculated to be high, the positive predictive value is
likely to be high as well in situations in which the prevalence of
leptospirosis among patients with suspected leptospirosis is
high. From the results of this study the positive predictive value
was calculated to be 93.7% for samples collected during the
first 10 days of the disease and 98.1% for samples collected at
a later stage. In situations in which leptospirosis is rare, how-
ever, the positive predictive value is likely to be lower, and in
that case a positive result ideally should be confirmed by fur-
ther laboratory testing, preferably by MAT.
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